Latest News
Bausch Health to Announce Third Quarter 2024 Results on October 30, 2024
LAVAL, QC / ACCESSWIRE / October 9, 2024 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) will release third quarter 2024 financial results after market close on Wednesday, October 30, 2024. Bausch Health will host a conference call and live...
The potential sale of Bausch + Lomb, Bausch Health's eye care business, could result in a financial gain for the company by reducing its debt burden.
Health Canada Approves (Pr)CABTREO(TM) (clindamycin phosphate, adapalene and benzoyl peroxide) Triple-Combination Topical Treatment for Acne Vulgaris in Patients 12 Years of Age and Older
LAVAL, QC / ACCESSWIRE / September 11, 2024 / Bausch Health, Canada Inc., part of Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) today announced the approval by Health Canada of PrCABTREOTM (clindamycin phosphate, adapalene and benzoyl peroxide)...
Bausch Health Responds to Market Rumors
LAVAL, QC / ACCESSWIRE / July 24, 2024 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) (the "Company") has become aware of a news article issued by Reorg® today, citing unnamed sources.
The biggest points detractor from index returns hasn’t changed since our last update, but the biggest contributor might come as a bit of a surprise
Bausch Health Announces 2024 Annual Meeting of Shareholder Results
LAVAL, QC / ACCESSWIRE / May 15, 2024 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) today announced the results of its 2024 annual meeting of shareholders.
Bausch Health Announces Updates Related to Norwich XIFAXAN Matters
LAVAL, QC / ACCESSWIRE / May 14, 2024 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) and its gastroenterology business Salix Pharmaceuticals, today announced certain updates related to its litigation with Norwich Pharmaceuticals, Inc.
Why Bausch Health Companies Stock Dived by More Than 7% Today
A large red number on the bottom line attracted the wrong kind of investor attention for the company.
Bausch Health Companies had the 8th-highest Vol/OI ratio in Wednesday trading. The pharmaceutical company’s unusual options activity suggests it might have more gains ahead.
Salix in Collaboration with The U.S. Pain Foundation and the International Foundation for Gastrointestinal Disorders Establish the Inaugural Opioid-Induced Constipation (OIC) Awareness Day
BRIDGEWATER, NJ / ACCESSWIRE / December 5, 2023 / Salix Pharmaceuticals, the gastroenterology division of Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC), The U.S. Pain Foundation (USPF), and The International Foundation for Gastrointestinal...
The Absence of an Overt Hepatic Encephalopathy (OHE)-Specific Diagnosis Code May Result in Increased OHE-Related Length of Stay and Hospitalization-Related Costs Due to OHE Rate Underestimation, According to New Analysis
Lack of OHE-specific diagnostic code in hospitals may increase risk of additional cost, length of hospitalization and additional burdens for patients compared to those with a previous primary OHE diagnosis
CORRECTION BY SOURCE: The Absence of an Overt Hepatic Encephalopathy (OHE)-Specific Diagnosis Code May Result in Increased OHE-Related Length of Stay and Hospitalization-Related Costs Due to OHE Rate Underestimation, According to New Analysis
This corrects and replaces the release that was disseminated earlier today
As Daylight Saving Time Comes to a Close, Bausch Health Champions Mental Health with a Spotlight on Preventing Seasonal Affective Disorder (SAD)
Company Introduces Multimedia Resources to Bring Awareness of SAD
Bausch Health Announces Third-Quarter 2023 Results
LAVAL, QC / ACCESSWIRE / November 2, 2023 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) ("Bausch Health" or the "Company" or "we" or "our") today announced its third-quarter 2023 financial results and other key updates from the quarter.
U.S. District Court Dismisses Norwich's Lawsuit Against the FDA
LAVAL, QC / ACCESSWIRE / November 1, 2023 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC), and its gastroenterology business Salix Pharmaceuticals, Inc., today announced that the U.S. District Court for the District of Columbia in the matter of...
Bausch Health Unveils "Looking Forward" - A New DTC Television Campaign for Seasonal Affective Disorder (SAD)
First-Ever Television Ad Campaign for APLENZIN® (bupropion hydrobromide) Airs in October
FDA Approves Cabtreo(TM) (Clindamycin Phosphate, Adapalene and Benzoyl Peroxide) Topical Gel for the Treatment of Acne Vulgaris in Patients Twelve Years of Age and Older
First and only FDA-approved fixed-dose, triple-combination topical treatment
New Analysis Indicates That a Majority of Overt Hepatic Encephalopathy (OHE) Patients May Face Delays in Treatment Initiation and Gaps During Treatment for Access to Treatment Indicated to Reduce Risk for OHE Recurrence
Hurdles Led to Almost All Patients Having At Least One Day Delay to Receive Treatment with Xifaxan®
Bausch Health to Announce Third-Quarter 2023 Results on Nov. 2
LAVAL, QC / ACCESSWIRE / October 12, 2023 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) will release its third-quarter financial results on Thursday, Nov. 2, 2023. Bausch Health will host a conference call and live webcast at 8:00 a.m. U.S....
Salix Pharmaceuticals Releases Liver Health Annual Trends Report Identifying Increase in Chronic Liver Disease and Cirrhosis-Related Deaths Marking These as Ninth Leading Cause of Death in U.S.
LAVAL, QC / ACCESSWIRE / October 10, 2023 / Salix Pharmaceuticals, the gastroenterology business of Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC), today released the Salix Liver Health Trends Report, Third Edition, which documents the evolving...
Salix Pharmaceuticals Partners with Bellamy Young
Bellamy Young is Moving Past Stigma as She Speaks Candidly about Her Father's Struggle with Chronic Liver Disease/Cirrhosis and Resulting Hepatic Encephalopathy
Bausch Health's Bausch + Lomb Announces Completion of the Acquisition of XIIDRA(R)
LAVAL, QC / ACCESSWIRE / September 29, 2023 / Bausch + Lomb Corporation ("Bausch + Lomb") (NYSE/TSX:BLCO), a subsidiary of Bausch Health Companies Inc. (the "Company" or "Bausch Health") (NYSE/TSX:BHC), today announced it has completed its...
BHC FINAL DEADLINE ALERT: ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Bausch Health Companies Inc. Investors to Secure Counsel Before Important September 25 Deadline in Securities Class Action - BHC
WHY: NEW YORK, NY - (NewMediaWire) - September 23, 2023 - Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Bausch Health Companies Inc. (NYSE: BHC) between August 6, 2020 and May 3, 2023, both dates inclusive...
BHC Investors Have Opportunity to Lead Bausch Health Companies Inc. Securities Fraud Lawsuit
/PRNewswire/ -- Glancy Prongay & Murray LLP ("GPM") announces that investors with substantial losses have opportunity to lead the securities fraud class action...
BHC DEADLINE: ROSEN, A LEADING LAW FIRM, Encourages Bausch Health Companies Inc. Investors to Secure Counsel Before Important September 25 Deadline in Securities Class Action - BHC
/PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Bausch Health Companies Inc. (NYSE: BHC) between...